Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234790 | 0.92 | CTSS (0.36) | CTSSKDM4EALDH1A1SLC22A12MEN1 | |
| SCHEMBL2237875 | 0.88 | MAOA (0.38) | MAOAMAOBALDH1A1MEN1HPGD | |
| SCHEMBL2235680 | 0.85 | CTSS (0.36) | CTSSSLC22A12 | |
| SCHEMBL2233089 | 0.83 | GRM1 (0.37) | MAOAMAOBALDH1A1GLAMEN1 | |
| SCHEMBL2234654 | 0.82 | MET (0.41) | MAOAMAOBSMN1; SMN2METSCN9A | |
| SCHEMBL2237841 | 0.81 | MET (0.39) | MAOAMAOBSMN1; SMN2METSCN9A | |
| SCHEMBL2234146 | 0.81 | NCOA3 (0.36) | MAOAMAOBKDM4EALDH1A1GLA | |
| SCHEMBL2234500 | 0.81 | GSR (0.38) | MAOAMAOBALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2232780 | 0.81 | GSR (0.41) | MAOAMAOBALDH1A1KMT2ALMNA | |
| SCHEMBL2234572 | 0.81 | GSR (0.41) | MAOAMAOBMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | claimed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | claimed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | claimed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008024438-A2 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | GPR174, GPR17, PTGFR | CTSS 1484/4885MAOA 1369/4885MAOB 1164/4885 |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | GPR174, GPR17, PTGFR | CTSS 1484/4885MAOA 1369/4885MAOB 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.